130 results
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
Therapeutics, Inc. (“Tempest Therapeutics”). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
9 May 24
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
4:25pm
(the “Securities Act”)) concerning Tempest Therapeutics, Inc. These statements may discuss goals, intentions, and expectations as to future plans, trends
8-K
EX-99.1
evo8xz1
19 Mar 24
Tempest Reports Year End 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
2tk0s
8 Nov 23
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.2
fh13f9ge80dmplzjrk
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
8-K
EX-99.1
99ksamfj435qcc1m3w
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
8-K
EX-99.1
y4zvqu5
10 Aug 23
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
4:27pm
8-K
EX-99.1
fnfdxrwjf9asjkdosd5
10 May 23
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
nvodh1gqb jyik
28 Apr 23
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
8:30am
8-K
EX-99.1
hllns4mg dmfv
8 Nov 22
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
8:55am